Substituted furo[2,3-b]pyridine derivatives

Details Substituted furo[2,3-b]pyridine derivatives Substituted furo[2,3-b]pyridine derivatives

2006-08-15

2006-08-15

Davis, Zinna N. (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S115000

Reexamination Certificate

active

07091216

ABSTRACT:
Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

REFERENCES:
patent: 3960876 (1976-06-01), Curran
patent: 4973587 (1990-11-01), Ward et al.
patent: 5013837 (1991-05-01), Ward et al.
patent: 5338740 (1994-08-01), Carpino et al.
patent: 5489685 (1996-02-01), Houpis et al.
patent: 5596106 (1997-01-01), Cullinan et al.
patent: 5747524 (1998-05-01), Cullinan et al.
patent: 6028084 (2000-02-01), Barth et al.
patent: 6344474 (2002-02-01), Maruani et al.
patent: 2004/0024881 (2004-02-01), Elving et al.
patent: 2004/0157838 (2004-08-01), Griffith
patent: 2004/0157839 (2004-08-01), Griffith
patent: 2004/0214837 (2004-10-01), Griffith et al.
patent: 2004/0214838 (2004-10-01), Carpino et al.
patent: 2004/0214855 (2004-10-01), Carpino et al.
patent: 2004/0214856 (2004-10-01), Carpino et al.
patent: 0 250 131 (1991-11-01), None
patent: 0 737 685 (2000-07-01), None
patent: 2289276 (1995-11-01), None
patent: 1993004989 (1993-01-01), None
patent: 1993086064 (1993-04-01), None
patent: 1995053562 (1995-02-01), None
patent: WO 92/03427 (1992-03-01), None
patent: WO 96/02248 (1996-02-01), None
patent: WO 96/11929 (1996-04-01), None
patent: WO 96/23783 (1996-08-01), None
patent: WO 97/05139 (1997-02-01), None
patent: WO 97/08167 (1997-03-01), None
patent: WO 97/37989 (1997-10-01), None
patent: WO 98/32441 (1998-07-01), None
patent: WO 98/46609 (1998-10-01), None
patent: WO 99/02499 (1999-01-01), None
patent: WO 99/03859 (1999-01-01), None
patent: WO 01/28557 (2001-04-01), None
patent: WO 01/58450 (2001-08-01), None
patent: WO 02/42269 (2002-05-01), None
patent: WO 03/007887 (2003-01-01), None
patent: WO 03/027114 (2003-04-01), None
patent: WO 03/063781 (2003-08-01), None
patent: WO 03/075660 (2003-09-01), None
patent: WO 2003/077847 (2003-09-01), None
patent: WO 03/087037 (2003-10-01), None
patent: WO 2003/082190 (2003-10-01), None
patent: WO 2003/082191 (2003-10-01), None
patent: WO 2003/086288 (2003-10-01), None
patent: WO 2004/000832 (2003-12-01), None
patent: WO 2004/013120 (2004-02-01), None
patent: WO 2004/029204 (2004-04-01), None
patent: WO 2004/048317 (2004-06-01), None
patent: WO 2004/058145 (2004-07-01), None
patent: WO 2004/060882 (2004-07-01), None
patent: WO 2004/087704 (2004-10-01), None
patent: WO 2005/000301 (2005-01-01), None
patent: WO 2005/000809 (2005-01-01), None
patent: WO 2005/009479 (2005-02-01), None
patent: WO 2005/009870 (2005-02-01), None
patent: WO 2005/027837 (2005-03-01), None
patent: WO 2005/030732 (2005-04-01), None
Taylor et al., Tetrahedron, vol. 43 (1987), pp. 5145-5158, “Intramolecular diels-alder reactions of 1,2,4-triazines”.
Barth, Exp. Opin. Ther. Patents, vol. 8 (1998), pp. 301-313, “Cannabinoid receptor agonists and antagonists”.
Petitet et al., Emerging Drugs, vol. 3 (1998), pp. 39-53, “The therapeutic applications of cannabinoid agonists and antagonists”.
Grundy, Expert Opin. Investig. Drugs, vol. 11 (2002), pp. 1365-1374, “The therapeutic potential of the cannabinoids in neuroprotection”.
Goya et al., Exp. Opin. Ther. Patents, vol. 10 (2000), pp. 1529-1538, “Recent advances in cannabinoid receptor agonists and antagonists”.
Adam et al., Exp. Opin. Ther. Patents, vol. 12 (2002), pp. 1475-1489, “Recent advances in the cannabinoids”.
Le Foll et al., J. Pharm. & Exper. Ther., vol. 312 (2005), pp. 875-883, “Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence”.
Xiang et al, Ann. Reports in Med. Chem., vol. 34 (1999), pp. 199-208, “Chap. 20. Pharmacology of cannabinoid receptor agonists and antagonists”.
Database Chemcats, AN:2003:951109, 2003.

Affiliated with

Also associated with

Rating

Substituted furo[2,3-b]pyridine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Substituted furo[2,3-b]pyridine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted furo[2,3-b]pyridine derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3606216